The majority of patients with chronic kidney disease have hypertension, which is an independent risk factor for progression of kidney disease and cardiovascular disease. May 15, 2014. resistant hypertension, electrolyte abnormalities, chronic kidney disease, end stage renal disease, glomerular disease and kidney stones. Obstructive nephropathy: Disorders that block urinary flow such as kidney stones, enlarged prostate, or tumors. Obesity, while it usually does not in itself cause kidney disease, may increase the tendency to kidney damage from diabetes, hypertension, and certain other types of kidney disease. Weight loss may make diabetes easier to control, reduce blood pressure, and reduce protein leakage from the kidneys in some types of CKD. Hello, Medications for lowering blood pressure which can be used in kidney failure are angiotensin converting enzyme inhibitor since they protect your kidneys and lower the risk of heart disease. Moved Permanently. The document has moved here. Calcium Channel Blockers and Renal. prevalence of chronic kidney disease. Amlodipine did seem to be equally effective as the. It may then be increased to 4 mg once daily depending on the effect of the medication and side effects. Common Questions and Answers about Norvasc kidney damage norvasc hi, the short answer is that the second drugs are known to directly protect the kidneys (ACEI or ARB drugs) you can actually lower BP with other types of drugs, and kidney damage still can go on yet the Norvasc is doing well to lower your BP. The National Kidney Foundation is the leading organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. Norvasc (amlodipine) is a calcium channel blocker that dilates (widens) blood vessels and improves blood flow. Norvasc is used to treat chest pain and other conditions caused by coronary artery disease. Norvasc has been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, coronary artery disease, peripheral vascular disease, diabetes mellitus, and abnormal lipid profiles.